What is the recommended dose of Celexa (citalopram) for adults and adolescents with depression?

Citalopram (Celexa) Dosing Recommendations

For adults under 60 years, start citalopram at 20 mg once daily with a maximum dose of 40 mg/day; for adults 60 years and older, start at 10-20 mg daily with a maximum of 20 mg/day due to dose-dependent QT prolongation risk. 1, 2

Standard Adult Dosing (Age <60 Years)

• Initial dose: 20 mg once daily 1, 2
• Dose titration: May increase after 1-2 weeks if clinical response is insufficient 1
• Maximum dose: 40 mg/day (FDA boxed warning due to QT prolongation risk) 3, 1, 2
• Time to full therapeutic effect: 4-8 weeks at therapeutic doses 1

Elderly Patients (Age ≥60 Years)

• Initial dose: 10 mg once daily (approximately 50% of standard adult starting dose) 1, 2
• Maximum dose: 20 mg/day (mandatory reduction due to 30-50% increased half-life and 23-30% increased drug exposure) 3, 1, 2
• The pharmacokinetic changes in elderly patients substantially increase QT prolongation risk, making this dose ceiling non-negotiable 2

Special Population Dose Reductions (Maximum 20 mg/day)

Hepatic impairment:

• Start at 10 mg/day with maximum of 20 mg/day due to 37% reduction in clearance and doubled half-life 1, 2

CYP2C19 poor metabolizers:

• Maximum dose 20 mg/day due to 68% increased peak levels and 107% increased drug exposure 1, 2

Patients taking CYP2C19 inhibitors (omeprazole, cimetidine):

• Maximum dose 20 mg/day due to significantly reduced citalopram clearance 1, 2

Adolescents

• Safety and effectiveness not established in pediatric populations 2
• Open-label data suggest 20-40 mg/day may be moderately effective for depression and anxiety in ages 7-18, though this is off-label use 4
• Regular monitoring of weight and growth is essential if used in children/adolescents 2

Treatment Duration

• First episode of major depression: Continue for at least 4-12 months after remission 1
• Recurrent depression: Prolonged maintenance treatment recommended at the same dose that achieved remission 1, 5
• Research demonstrates that full-dose maintenance (not reduced doses) is more effective for preventing recurrence 5, 6

Critical Safety Monitoring

QT prolongation risk:

• This is dose-dependent and the primary reason for mandatory dose ceilings 3, 2
• Risk is present at initiation but typically depends on coexisting risk factors 3
• Regular ECG monitoring recommended when initiating or adjusting doses, especially in elderly patients 1

Hyponatremia:

• Occurs in 0.5-12% of older adults taking SSRIs, typically within the first month 3
• Elderly patients are at substantially greater risk 2

Suicidality:

• Slightly increased risk in adults 18-24 years (OR 2.30) 3
• Monitor within 1-2 months of initiation or dose increase 3

Common Pitfalls to Avoid

• Do not exceed 40 mg/day in adults <60 years or 20 mg/day in adults ≥60 years - this violates FDA boxed warnings regarding QT prolongation 3, 2
• Do not assume treatment failure before 4-6 weeks at therapeutic doses, as full antidepressant effect requires this duration 1
• Do not abruptly discontinue - taper gradually over minimum 10-14 days to limit withdrawal symptoms 1
• Do not use reduced maintenance doses - patients with recurrent depression should continue the full dose that achieved remission 5, 6

Discontinuation Protocol

• Taper gradually over 10-14 days minimum to prevent withdrawal symptoms 1
• Withdrawal symptoms are more likely with abrupt cessation after prolonged use 1